Skip to main content

Revenue Cycle

Electronic Health Records
By Jessica Davis | 01:41 pm | November 14, 2017
At the AMA’s interim meeting over the weekend, David Barbe, MD, told group members that AMA is making progress to improve the usability of EHRs, mobile devices and interoperability.
Analytics
By Mike Miliard | 04:35 pm | November 13, 2017
But just 19 percent of LTPAC organizations have some technological capabilities of EHRs operational, report shows. Only 3 percent are using analytics to improve quality and efficiency.
Revenue Cycle
By Beth Jones Sanborn | 02:03 pm | November 13, 2017
Only seven states have little to no activity around value-based payment models, a study by Change Healthcare found.
Accountable Care
By Jacques Mulder | 05:12 pm | November 07, 2017
If value-based care is to take shape, it’s critical that providers actively engage with patients to help them better understand the true cost of care.
Analytics
By Jeff Lagasse | 11:32 am | November 03, 2017
New Mexico hospital leans on Zoeticx tech to bridge the gap between medical quality and patient care.
Electronic Health Records
By Mike Miliard | 04:14 pm | November 02, 2017
After acquiring McKesson’s EHR business, Allscripts pledges to invest in integration, innovation and interoperability for better population health management.
Analytics
By Bernie Monegain | 02:51 pm | November 02, 2017
Personalized medicine, big data and analytics, virtual care are driving up investments in digital startups, Accenture says.
Electronic Health Records
By Susan Morse | 11:17 am | November 02, 2017
The new program and expected final MACRA rule are proof that new administration is serious about scaling back requirements.
Electronic Health Records
By Wendy Almeida | 01:04 pm | November 01, 2017
Solving interoperability problems for some hospitals has involved EHR go-live projects that align with strategic planning to find solutions – and spending money where the priorities are.
Revenue Cycle
By Jessica Davis | 03:00 pm | October 27, 2017
Third-quarter revenue for the global pharma giant was drastically reduced in part by the temporary production shutdown, higher demand than planned and lost sales in certain markets due to the virus.